← Back to Search

Stem Cell Therapy

Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose for Diabetic Kidney Disease

Phase 1
Waitlist Available
Led By LaTonya J Hickson, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through month 15
Awards & highlights

Study Summary

This trial will test if intra-arterially delivered autologous adipose tissue-derived mesenchymal stem/stromal cells are safe and effective in treating patients with progressive diabetic kidney disease.

Eligible Conditions
  • Diabetic Kidney Disease
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Chronic Kidney Disease
  • Kidney Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through month 15
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through month 15 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events
Secondary outcome measures
Kidney Function

Trial Design

2Treatment groups
Experimental Treatment
Group I: Lower Dose MSCExperimental Treatment1 Intervention
This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Lower Dose.
Group II: Higher Dose MSCExperimental Treatment1 Intervention
This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Higher Dose

Find a Location

Who is running the clinical trial?

Regenerative Medicine MinnesotaUNKNOWN
Mayo ClinicLead Sponsor
3,245 Previous Clinical Trials
3,783,450 Total Patients Enrolled
LaTonya J Hickson, MDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
60 Total Patients Enrolled
~0 spots leftby Jun 2025